Oneview Healthcare (ONE) H1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2026 earnings summary
26 Aug, 2026Executive summary
Recurring revenue grew 13% year-over-year to €4.3 million, now representing 79% of total revenue, while total revenue declined 14% to €5.5 million due to lower non-recurring contributions.
Gross margin increased nine points to 70% (up from 61%), maintaining gross profit at €3.8 million despite lower revenue.
Operating EBITDA loss improved by 11% year-over-year to €4.0 million, reflecting cost discipline and restructuring.
Cash position at June 30 was €7.2 million, with a pro forma balance of €11.4 million after a A$19 million placement.
Strategic initiatives included the launch of Bedside Hub, Epic certification, and inclusion in a major US health system's procurement framework.
Financial highlights
Recurring revenue up 13% year-over-year; non-recurring revenue down 54%.
Gross margin improved to 70% (up from 61% year-over-year).
Cash operating expenses reduced by 6% to €7.8 million, mainly from lower employee costs.
Operating cash outflow decreased 15% year-over-year to €4.1 million.
Net assets increased 73% since December 2025, driven by capital raise.
Outlook and guidance
Management is focused on reaching cash flow breakeven, leveraging recurring revenue growth and cost efficiencies.
Bedside Hub is expected to accelerate sales cycles and provide a lighter-touch deployment, targeting cost-conscious segments.
Pipeline includes 16 Bedside Hub opportunities representing over 20,000 beds, with pilots underway at major US health systems.
Targeting 3-4 new Bedside Hub logo wins and continued ARR growth.
First deployments of the new front end and Ovie pilots scheduled for H2 2026.
Latest events from Oneview Healthcare
- AI-powered orchestration transforms patient care, driving efficiency and restoring time for clinicians.ONE
Investor presentation - Cash position strengthened by equity raise, with improved operating cash flow and strong sales pipeline.ONE
Q1 2026 TU - 21% revenue growth and AI product launches drive expansion amid margin and regulatory risks.ONE
H2 2025 - Q3 2025 saw higher cash outflow but strong sales momentum and new customer deployments.ONE
Q3 2025 TU - 36% revenue growth, AI innovation, and restructuring set up a stronger H2 2025.ONE
H1 2025 - Baxter partnership expanded to Canada; all AGM resolutions passed with overwhelming support.ONE
AGM 2024 - Recurring revenue up 8% and gross margin at 73%, with US growth driven by Baxter partnership.ONE
H1 2024 - Revenue up 5% to €9.9M, losses widen, but cash and US growth support future expansion.ONE
H2 2024